Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV-Allo: Phase II randomized RSV vaccination in allogeneic HSCT recipients
2024-513290-53-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Oct 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in respiratory syncytial virus disease (RSV) comparing Abrysvo vaccination with Arexvy vaccination (2 arms). Primary endpoints: Seroconversion-based vaccine efficacy for each RSV vaccine and Baseline immune signature predicting vaccine response. Planned start Oct 2024; status: authorised.
02
Drugs
RSVpreF vaccineGSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2024-513290-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513290-53-00.